Home Clinical Topics FDA updates Tasigna label to include stop treatment options

FDA updates Tasigna label to include stop treatment options

Author(s):

On Dec. 22, the U.S. Food and Drug Administration (FDA) updated the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here